The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective
- PMID: 12814957
- DOI: 10.1124/dmd.31.7.815
The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective
Abstract
Current regulatory guidances do not address specific study designs for in vitro and in vivo drug-drug interaction studies. There is a common desire by regulatory authorities and by industry sponsors to harmonize approaches, to allow for a better assessment of the significance of findings across different studies and drugs. There is also a growing consensus for the standardization of cytochrome P450 (P450) probe substrates, inhibitors and inducers and for the development of classification systems to improve the communication of risk to health care providers and to patients. While existing guidances cover mainly P450-mediated drug interactions, the importance of other mechanisms, such as transporters, has been recognized more recently, and should also be addressed. This article was prepared by the Pharmaceutical Research and Manufacturers of America (PhRMA) Drug Metabolism and Clinical Pharmacology Technical Working Groups and represents the current industry position. The intent is to define a minimal best practice for in vitro and in vivo pharmacokinetic drug-drug interaction studies targeted to development (not discovery support) and to define a data package that can be expected by regulatory agencies in compound registration dossiers.
Comment in
-
A method for identification of inhibition mechanism and estimation of Ki in in vitro enzyme inhibition study.Drug Metab Dispos. 2003 Nov;31(11):1456-7. doi: 10.1124/dmd.31.11.1456. Drug Metab Dispos. 2003. PMID: 14570779 No abstract available.
Similar articles
-
The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective.J Clin Pharmacol. 2003 May;43(5):443-69. J Clin Pharmacol. 2003. PMID: 12751267 Review.
-
In vitro and in vivo induction of cytochrome p450: a survey of the current practices and recommendations: a pharmaceutical research and manufacturers of america perspective.Drug Metab Dispos. 2009 Jul;37(7):1339-54. doi: 10.1124/dmd.109.027029. Epub 2009 Apr 23. Drug Metab Dispos. 2009. PMID: 19389860
-
Emerging role of drug interaction studies in drug development: the good, the bad, and the unknown.Psychopharmacol Bull. 2001 Autumn;35(4):80-93. Psychopharmacol Bull. 2001. PMID: 12397858 Review.
-
New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process.J Clin Pharmacol. 2008 Jun;48(6):662-70. doi: 10.1177/0091270007312153. Epub 2008 Mar 31. J Clin Pharmacol. 2008. PMID: 18378963 Review.
-
[Development of antituberculous drugs: current status and future prospects].Kekkaku. 2006 Dec;81(12):753-74. Kekkaku. 2006. PMID: 17240921 Review. Japanese.
Cited by
-
Prevalence of potential drug-drug interactions and associated factors among outpatients and inpatients in Ethiopian hospitals: a systematic review and meta-analysis of observational studies.BMC Pharmacol Toxicol. 2020 Aug 24;21(1):63. doi: 10.1186/s40360-020-00441-2. BMC Pharmacol Toxicol. 2020. PMID: 32831135 Free PMC article.
-
Exploration of cytochrome P450 inhibition mediated drug-drug interaction potential of kratom alkaloids.Toxicol Lett. 2020 Feb 1;319:148-154. doi: 10.1016/j.toxlet.2019.11.005. Epub 2019 Nov 7. Toxicol Lett. 2020. PMID: 31707106 Free PMC article.
-
A quantitative framework and strategies for management and evaluation of metabolic drug-drug interactions in oncology drug development: new molecular entities as object drugs.Clin Pharmacokinet. 2010 Nov;49(11):703-27. doi: 10.2165/11536740-000000000-00000. Clin Pharmacokinet. 2010. PMID: 20923246
-
Evaluation of drug-drug interactions between midostaurin and strong CYP3A4 inhibitors in patients with FLT-3-mutated acute myeloid leukemia (AML).Cancer Chemother Pharmacol. 2022 Jul;90(1):19-27. doi: 10.1007/s00280-022-04448-w. Epub 2022 Jun 25. Cancer Chemother Pharmacol. 2022. PMID: 35751657 Clinical Trial.
-
Inhibition of Rat CYP1A2 and CYP2C11 by Honokiol, a Component of Traditional Chinese Medicine.Eur J Drug Metab Pharmacokinet. 2019 Dec;44(6):787-796. doi: 10.1007/s13318-019-00565-9. Eur J Drug Metab Pharmacokinet. 2019. PMID: 31175627
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
